Author:
Eteleeb Abdallah M.,Novotny Brenna C.,Tarraga Carolina Soriano,Sohn Christopher,Dhungel Eliza,Brase Logan,Nallapu Aasritha,Buss Jared,Farias Fabiana,Bergmann Kristy,Bradley Joseph,Norton Joanne,Gentsch Jen,Wang Fengxian,Davis Albert A.,Morris John C.,Karch Celeste M.,Perrin Richard J.,Benitez Bruno A.,Harari Oscar
Abstract
Unbiased data-driven omic approaches are revealing the molecular heterogeneity of Alzheimer disease. Here, we used machine learning approaches to integrate high-throughput transcriptomic, proteomic, metabolomic, and lipidomic profiles with clinical and neuropathological data from multiple human AD cohorts. We discovered 4 unique multimodal molecular profiles, one of them showing signs of poor cognitive function, a faster pace of disease progression, shorter survival with the disease, severe neurodegeneration and astrogliosis, and reduced levels of metabolomic profiles. We found this molecular profile to be present in multiple affected cortical regions associated with higher Braak tau scores and significant dysregulation of synapse-related genes, endocytosis, phagosome, and mTOR signaling pathways altered in AD early and late stages. AD cross-omics data integration with transcriptomic data from an SNCA mouse model revealed an overlapping signature. Furthermore, we leveraged single-nuclei RNA-seq data to identify distinct cell-types that most likely mediate molecular profiles. Lastly, we identified that the multimodal clusters uncovered cerebrospinal fluid biomarkers poised to monitor AD progression and possibly cognition. Our cross-omics analyses provide novel critical molecular insights into AD.
Funder
National Institute on Aging
National Institute of Neurological Disorders and Stroke
Chan Zuckerberg Initiative
Beth Israel Deaconess Medical Center
Archer Foundation
Knight Alzheimer Disease Research Center
Publisher
Public Library of Science (PLoS)